Clinical trial data presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders showed that pimavanserin had positive efficacy in patients showing Parkinson Disease psychosis symptoms who were treated earlier.
Louie Pasculli
Advertisement
Assistant Editor for NeurologyLive
Articles by Louie Pasculli
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
A Step Forward in Multiple System Atrophy: Phase 2 Findings Reinforce ATH434’s Disease-Modifying Potential
2
NeuroVoices: Gerald Maguire, MD, on Raising Awareness of the Neurobiology of Stuttering
3
Trappsol Cyclo Shows Promising Results in Newborns With Niemann Pick Disease Type C1
4
Incorporating AI Into Stroke Triage
5
